A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
Study Identifier:
CLI-10067AA1-02
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
EU CT ID:
Study Contact Information:
Recruiting
Study Details
Medical Condition
- Idiopatic Pulmonary Fibrosis
Study Drug
- Drug: CHF10067
Date
Jul 2026 - Jun 2028
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 40+ years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
- Informed consent: Participant's written informed consent obtained prior to any study-related procedure.
- Sex and age: Male or female, of any race and ethnicity, aged ≥40 years with a life expectancy of at least 1 year at screening in the opinion of the Investigator.
- Body weight ≥45 kg.
- Diagnosis of IPF: Diagnosis as defined by the 2018 and 2022 American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Society Guidelines for a maximum 8 years before screening. The most recent High-resolution computed tomography (HRCT) ≤6 months prior to screening, reviewed by central reading, should be used to confirm the diagnosis.
- Lung function: FVC ≥45% of predicted normal value and a ratio of forced expiratory volume in the first second (FEV1)/FVC ≥0.7 at screening.
- Diffusing capacity of the lung for carbon monoxide (DLCO) corrected for haemoglobin ≥25% of predicted normal at screening.
- Oxygen saturation measured by pulse oximetry (peripheral capillary oxygen saturation \[SpO2\]) \>90% at rest when the maximum oxygen flow is 4 L/min by standard nasal cannula or the equivalent oxygen delivery via reservoir nasal cannula (≤2 L/min).
Exclusion Criteria
- Participant with a documented diagnosis of coeliac disease.
- Low respiratory tract infection: Documented low respiratory tract infection in the last 4 weeks prior to screening or documented acute exacerbation of IPF (defined as acute worsening or development of dyspnoea typically \<1 month duration;
- Lung cancer: Active diagnosis or history of lung cancer.
- Emphysema: HRCT (refer to inclusion criterion \[Diagnosis of IPF\]), reviewed by central reading, shows the presence of emphysema ≥20% or that the extent of emphysema is greater than the extent of fibrosis.
- Organ transplantation: End-stage fibrotic disease expected to require organ transplantation within 6 months from screening.
- Other medical conditions: Clinically relevant and uncontrolled pulmonary (including any non-IPF pulmonary diagnosis), cardiac, hepatic, gastrointestinal, renal, endocrine, metabolic, neurologic, psychiatric disorders, active or untreated latent tuberculosis/tuberculosis infection that may interfere with the participant's ability to complete this study according to the Investigator's judgement.
- Any other comorbid non-IPF pulmonary condition that may impact FVC according to the Investigator's judgement. Emphysema is allowed, unless it meets the above exclusion criterion regarding emphysema.
- Participant currently treated, or been treated with cytotoxic and immunosuppressant/modulator drugs within 48 weeks prior to screening. Systemic (IV, intramuscular, or oral) corticosteroids prednisone- equivalent dose of \>10 mg/day used for \>10 days.
- Hypersensitivity: Known intolerance and/or hypersensitivity to any of the excipients contained in the formulation or any other substance used in the study.
- History of allergic or anaphylactic reaction to human, humanised, chimeric immunoglobulins (Igs), or murine monoclonal antibodies.
Healthy Volunteers
No
Protocol Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis (IPF).
It is a phase IIb, multicentre, randomised, double-blind, placebo-controlled, three-arm parallel-group study.
A total of 240 participants with IPF (Idiomatic Pulmonary Fibrosis) will be randomised in approximately 150 investigational sites in North and Latin America, Europe, Asia, and Oceania.
Study Locations
Location
Status
Location
SEC Clinical Research LLC
Dothan, Alabama, United States, 36305
Contact: Marvin Sexton
Status
Recruiting
Location
Pasadena Center for Medical Research, Inc
St. Petersburg, Florida, United States, 33707
Contact: Mohamed Ali
Status
Recruiting
Location
Hannibal Regional Healthcare System, Inc.
Hannibal, Missouri, United States, 63401
Contact: Farah Humam
Status
Recruiting
Location
Clinical Research of Rock Hill
Rock Hill, South Carolina, United States, 29732
Contact: Michael Denenberg
Status
Recruiting
Location
Tennessee Comprehensive Lung and Sleep Center
Hendersonville, Tennessee, United States, 37075
Contact: Clyde Southwell
Status
Recruiting
Location
Premier Pulmonary Critical Care and Sleep Medicine, PA
Denison, Texas, United States, 75020
Contact: Sanober Kable
Status
Recruiting
Go to page